1 The Role of Exposure-Response Evaluation in Drug Development and Regulatory Decisions Case Study: Rosuvastatin Hae-Young Ahn, Ph.D. Office of Clinical.

Slides:



Advertisements
Similar presentations
Ramana S. Uppoor, M.Pharm., Ph.D., R.Ph.
Advertisements

Daniel Everitt, MD; Erica Egizi MPH Global Alliance for TB Drug Development, New York Helen Winter, PhD University of Otago, New Zealand 2012 International.
Statins in Renal Failure Andrea Fox Sunnybrook Health Science Center May 2010.
© 2006 National Lipid Association Statin Safety: Key Conclusions and Recommendations of the NLA.
CN-1 Everolimus Renal Safety and Efficacy Extrapolations, Dose Recommendations Lawrence Hunsicker, MD Professor of Medicine and Medical Director of Organ.
Assessment of Adalimumab Dose Selection for Adult Ulcerative Colitis Using Exposure-Response Analyses Michael Bewernitz1, Christine Garnett2,4, Klaus Gottlieb3,
Pharmacokinetics as a Tool
Clinical question: When do you get statin induced myopathy?
Pharmaceutical Development and Review Process Rev. 10/21/2014 APGO Interaction with Industry: A Medical Student Guide.
+ Drug Development and Review Process. + Objectives Learn the processes involved in drug discovery and development Define the phases involved in FDA drug.
Effectiveness Evaluation for Therapeutic Drugs for Non-Food Animals
Clinical Pharmacology Overview From the Antiviral Perspective Kellie Schoolar Reynolds, Pharm.D. Pharmacokinetics Team Leader Office of Clinical Pharmacology.
Charge to the Committee Kimberly Struble, Pharm.D. Regulatory Review Officer Division of Antiviral Drug Products.
Livalo (Pitavastatin)
AA-7-1 René Belder, MD Executive Director Clinical Development and Life Cycle Management Cardiovascular / Metabolics 7asdf.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 1 Improvement in Dose Selection: FDA Perspective IDSA/ISAP/FDA Workshop.
CE-1 CRESTOR ® Clinical Development Efficacy James W. Blasetto, MD, MPH Senior Director, Clinical Research.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 In Vitro/Animal Models to Support Dosage Selection: FDA Perspective.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production in Patients with Type 2 Diabetes.
Slide 1 EZT 2002-W-6022-SS Ezetimibe Co-administered with Statins: Efficacy and Tolerability Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
1 Kepivance™ (Palifermin) Basis for Approval and Pediatric Studies Kepivance™ (Amgen) Approved 12/15/04 Joseph E. Gootenberg, M.D. Office of Oncology Drug.
BackgroundBackground HDL-C levels are inversely related to CV event rates. HDL-C levels are inversely related to CV event rates. Torcetrapib, a cholesteryl.
Investigational Drugs in the hospital. + What is Investigational Drug? Investigational or experimental drugs are new drugs that have not yet been approved.
Praluent® - alirocumab
Quality Systems for Clinical Pharmacology and Biopharmaceutics Review Lawrence J. Lesko, Ph.D. Director, Office of Clinical Pharmacology and Biopharmaceutics.
Slide 1 EZT 2003-W SS Mechanism of Action and Pharmacology of Ezetimibe Copyright © 2003 MSP Singapore Company, LLC. All rights reserved.
CS-1 CRESTOR ® Safety Howard G. Hutchinson, MD Vice President, Clinical Research.
Drug - Device Combination Issues : Oncology Perspective Ramzi Dagher, M.D. DODP/CDER/FDA.
FDA Case Studies Pediatric Oncology Subcommittee March 4, 2003.
CI-1 CRESTOR ® (rosuvastatin calcium) Tablets Endocrinologic and Metabolic Drugs Advisory Committee Bethesda, Maryland July 9, 2003 C.
Proposal for End-of-Phase 2A (EOP2A) Meetings Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18, 2003 Lawrence.
Clinical Pharmacology Subcommittee of the Advisory Committee for Pharmaceutical Science Meeting April Quantitative risk analysis using exposure-response.
Statin Induce Myotoxicity
PO 2726; IAS; Vicriviroc (formerly SCH ): Antiviral Activity of a Potent New CCR5 Receptor Antagonist D. Schuermann, C. Pechardscheck, R. Rouzier,
CHEE 4401 Definitions drug - any substance that affects the structure or functioning of an organism pharmaceutics - the area of study concerned with the.
Endocrinologic & Metabolic Drugs Advisory Committee Meeting
Frequency of Proteinuria in Trial 99*
1 QTc and Quinolones: recent regulatory actions Joyce Korvick M.D., M.P.H. Office of Drug Evaluation IV Division of Special Pathogens FDA.
B-1 Pravastatin-Aspirin Combination René Belder, M.D. Executive Director Clinical Design and Evaluation, Metabolics Pharmaceutical Research Institute Bristol-Myers.
Sprout Pharmaceuticals Inc. FDA Approval Date: August 18, 2015
Phase I Issues for Novel TB Drugs Dakshina M. Chilukuri, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics, FDA OPEN FORUM ON KEY ISSUES IN TB.
July FUTURE of PHASE 1, 2, and 3 TRIALS Philip Colangelo, Pharm.D., Ph.D. Office of Clinical Pharmacology & Biopharmaceutics FDA / CDER.
Praxbind® - Idarucizumab
Regulatory Aspects of PK/PD – (modelling) Karolina Törneke Senior expert, member of the CVMP.
INTRODUCTION CLINICAL PHARMACOKINETICS
Systemic Exposure of Topical Tacrolimus Veneeta Tandon, Ph.D. Pharmacokinetics Reviewer Division of Pharmaceutical Evaluation III Office of Clinical Pharmacology.
Presented by Renato D. Lopes, MD, PhD, Duke Clinical Research Institute, Duke University, USA for the ARISTOTLE investigators. Efficacy and Safety of Apixaban.
Ameeta Parekh, Ph.D. CDER/OCPB CPSC Meeting November 17/18
Introduction to the Meeting Introduction to the Meeting Advisory Committee for Pharmaceutical Sciences Clinical Pharmacology Subcommittee November 17-18,
Applying New Science to Drug Safety Janet Woodcock, M.D. Acting Deputy Commissioner for Operations April 15, 2005.
Manufacturer: Amgen Inc FDA Approval Date: August 27, 2015
Chemical Structure of Rosuvastatin Relative lipophilicity * Rosuvastatin Cerivastatin Simvastatin Fluvastatin Atorvastatin Pravastatin.
Ezetimibe Overall Conclusions
Circulatory System Devices Panel Questions for Discussion EMBOL·X Aortic Filter October 23, 2002.
1 Pharmacokinetic Information Submitted to Support Valganciclovir Use in Maintenance Therapy for CMV Retinitis Robert O. Kumi, Ph.D. Reviewer, Pharmacokinetics.
Office of Clinical Pharmacology and Biopharmaceutics IDSA/ISAP/FDA Workshop 4/16/04 Current Status of Dose Selection in Antimicrobial Drug Development.
1 Biopharmaceutics Dr Mohammad Issa Saleh. 2 Biopharmaceutics Biopharmaceutics is the science that examines this interrelationship of the physicochemical.
Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT Ramana S. Uppoor, R.Ph., Ph.D. Division of Clinical Pharmacology-1 Office of Clinical Pharmacology, CDER, FDA.
The Heart Outcomes Prevention Evaluation (HOPE) – 3 Trial
Risk Factors for Linezolid-Associated Thrombocytopenia in Adult Patients Cristina Gervasoni Ospedale Luigi Sacco, Milano.
Topic #1: EOP2A Meetings Please comment on the goals of the proposed EOP2A meeting and the impact that such meetings could have on optimizing dose selection.
Methods to Adjust Doses Based on Exposure-Response Information Points to Consider Richard Lalonde Clinical Pharmacokinetics and Pharmacodynamics Pfizer.
Eucrisa™ - Crisaborole
Prof. Dr. Basavaraj K. Nanjwade
Senior Medical Director, Cardiovascular
Biopharmaceutics Dr Mohammad Issa Saleh.
Up to Date on Which NOAC for Which Patient
Guidelines for Initiation of Therapy
Major classes of drugs to reduce lipids
Presentation transcript:

1 The Role of Exposure-Response Evaluation in Drug Development and Regulatory Decisions Case Study: Rosuvastatin Hae-Young Ahn, Ph.D. Office of Clinical Pharmacology and Biopharmaceutics Division of Pharmaceutical Evaluation 2

2 Clinical Pharmacology Therapeutic area: –Lipid lowering Mechanism of Action: –Competitive inhibition of HMG-CoA reductase Pharmacokinetics –Absolute BA: about 20% –Food: ↓Cmax 20%, ↔ AUC –Metabolism: not extensively metabolized –Cyp P450 2C9 –Elimination t½: 19 hr

3 Clinical Pharmacology (Cont’d) Race: –Japanese and Chinese ancestry: 2x ↑ Renal Insufficiency: –Severe: 3x ↑ Drug-Drug Interactions –Cyclosporine:C max, AUC – ↑11x, 7x –Gemfibrozil:C max, AUC – ↑2x, 2x

4 Regulatory Activities June 2001, NDA submission –Proposed doses of 10, 20, 40, and 80 mg. May 2002, approvable –80 mg: not approvable --little added benefit, safety concerns –10 mg, 20 mg, 40 mg: approvable Additional safety data on 20 and 40 mg; Address renal issue Assess optimal dosing and others August 2003, approval – mg

5 How could exposure-response (or PK-PD) guide ‘optimal dosing’ for rosuvastatin?

6 LDL-C: % Change From Baseline Rosuvastatin vs Placebo Trials 8 and 23 Pooled (Wk 6) P <.001 vs placebo; data presented as LS mean ± SE Placebo n = Baseline characteristics Mean age: 56 yr Mean LDL-C: 190 mg/dL

7 Exposure-Response Relationship

8 PK/PD Model

9 Incidence of CK elevations and myopathy seen in phase II/III Baycol Rosuva All marketed STATINS a (mg)CK>10xULNMYOPATHY (all cases) % % % % Pbo0%0% 50.4%0.2% 100.2%0.1% 200.2%0.1% 400.4%0.2% 801.9%1.0% %0-0.5%

10 % of patients with proteinuria (  ++) At any visit Data from AV_LUBR, i.e. All controlled/Uncontrolled & RTLD Pools

11 Plasma rosuvastatin concentrations by dose in 6 patients with rhabdomyolysis or renal toxicity

12 Dosing considerations AUC C max Gemfibrozil 2x 2x Japanese Ancestry 2x 2x Severe Renal Insufficiency 3x 3x (CrCL < 30 mL/min) Cyclosporine 7x 11x

13 Precautions - General in Labeling Pharmacokinetic studies show.. 2-fold elevation in median exposure in Japanese subjects residing in Japan and in Chinese subjects residing in Singapore compared with Caucasians residing in North America and Europe….. these increases should be considered … dosing decisions for..Japanese and Chinese ancestry ( see WARNINGs Myopathy/Rhabdomyolysis; CLINICAL PHARMACOLOGY, Special Populations, Race).

14 Dosage and Administration in Labeling <Crestor® approved labeling; Hypercholesterolemia and mixed dislipidemia: (baseline LDL-C < 190mg/dL) Dose range: 5 to 40 mg once daily- individualized - usual recommended starting dose is 10 mg - 5 mg may be… less aggressive LDL-C reductions or predisposing factors for myopathy…

15 Dosage and Administration in Labeling (cont’d) Limit maximal doses –Cyclosporin5 mg –Gemfibrozil10mg –Severe RF5 – 10mg <Crestor® approved labeling;

16 Conclusion Expose-Response clearly shows Although the sponsor has proposed doses of 10, 20, 40, and 80mg, doses lower than 10mg have potential clinical utility. There is apparent relationship between adverse events and plasma concentrations of the drug. Findings from Exposure-Response relationships were used in recommendation for dosing adjustments.